3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Colorectal Neoplasms
200
Breast Neoplasms
124
Carcinoma, Non-Small-Cell Lung
121
Glioblastoma
93
Neoplasms
75
Ovarian Neoplasms
72
Rectal Neoplasms
61
Brain Neoplasms
59
Lung Neoplasms
56
Colonic Neoplasms
55
Neoplasm Metastasis
51
Glioma
49
Carcinoma, Renal Cell
46
Fallopian Tube Neoplasms
38
Gliosarcoma
35
Pancreatic Neoplasms
31
Carcinoma, Hepatocellular
28
Melanoma
26
Adenocarcinoma of Lung
24
Astrocytoma
21
Stomach Neoplasms
20
Uterine Cervical Neoplasms
16
Recurrence
16
Prostatic Neoplasms
16
Liver Neoplasms
16
Adenocarcinoma, Bronchiolo-Alveolar
16
Esophageal Neoplasms
15
Adenocarcinoma
15
Carcinoma, Ovarian Epithelial
14
Kidney Neoplasms
13
Interventions
Paclitaxel
6
Carboplatin
6
Radiotherapy
5
Chemotherapy, Adjuvant
5
Cyclophosphamide
4
Trastuzumab
3
Tamoxifen
3
Letrozole
3
Doxorubicin
3
Brachytherapy
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
pertuzumab
2
Surgical Procedures, Operative
2
Radiotherapy, Conformal
2
Magnetic Resonance Spectroscopy
2
Epirubicin
2
talimogene laherparepvec
1
sargramostim
1
palbociclib
1
ferric carboxymaltose
1
atezolizumab
1
atamestane
1
aldesleukin
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
VPS Coriolus versicolor extract
1
Toremifene
1
Thiotepa
1
Therapeutics
1
Reverse Transcriptase Polymerase Chain Reaction
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Ductal, Breast
×
Bevacizumab
×
Clear all
NCT01426880
2016-02-15
GeparSixto
GBG Forschungs GmbH
Phase 2/3
Completed
595 enrolled